Ruifu Therapeutics

Ruifu Therapeutics is a China-based biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design small molecules, including PROTACs and molecular glues, aimed at previously undruggable targets in oncology and immunology. Founded by industry veterans and backed by prominent venture capital firms such as Qiming Venture Partners and Lilly Asia Ventures, Ruifu focuses on addressing significant unmet medical needs through innovative medicinal chemistry and structural biology. Its pipeline is currently in the discovery and pre-clinical stages, targeting high-value pathways in cancer progression.